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Background: Tolerance and response to antiviral HCV treatment is poor in advanced ﬁbrosis.
The  aim of this study was to assess SVR rate and its predictive factors in HCV advanced
ﬁbrosis  patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the
adverse  events related to treatment.
Methods: A multicentric, retrospective study was conducted at six university hospitals.
METAVIR  F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV
had  their data analyzed. A stepwise logistic regression analysis was performed to identify
the  variables independently related to SVR. Adverse events were recorded during treatment.
Results:  308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was
present  in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was
5  (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were  nonresponders. SVR
rates  were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR
rates  according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent
factors  related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points.
Treatment  interruption occurred in 31% patients and death occurred in 1.9%, all with liver
cirrhosis.t of HConclusion:  TreatmenHowever,  a very careful ev
is  indicated and careful m
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ntroduction
epatitis C virus (HCV) infects more  than 170 million peo-
le  worldwide, and is the leading cause of hepatocellular
arcinoma and liver transplantation in the western world.1
hen cirrhosis is established, the risk of clinical decom-
ensation is high. Furthermore, tolerance and response to
ntiviral  treatment in advanced ﬁbrosis is poor.2–4 Neverthe-
ess,  achievement of a sustained virological response (SVR) in
hese patients reduces the incidence of hepatic decompensa-
ion  as well as the development of hepatocellular carcinoma
nd  death.5–7 Recently, a meta-analysis showed that even
f  SVR is not achieved, interferon therapy could be asso-
iated  with prevention of HCC development.7 Hence, HCV
nfection  eradication in this population might be stimu-
ated.
However, results on therapeutic efﬁcacy trials with patients
ith  advanced ﬁbrosis are hetereogeneous, and many  stud-
es  consist of sub-analyses from pivotal trials.8,9 Real life
tudies  in this population are scarce. In addition, data is
eterogeneous comprising different treatment schedules like
lpha interferon (IFN) or alpha Pegylated interferon (PEG-IFN)
ither  as monotherapy or associated to ribavirin (RBV).2,5,10,11
ith the recent approval of the protease inhibitors for HCV
reatment  new adverse events will occur and this might
e  balanced in this speciﬁc population. However, in many
ountries  these drugs have not yet been approved and patients
ith  advanced ﬁbrosis are still treated with the associa-
ion  of PEG-IFN and RBV. Notwithstanding, the combination
f  PEG-IFN and RBV will still be necessary for the treat-
ent  with the current protease inhibitors. Thus, the aim
f  this study was  to assess the rate of SVR and its predic-
ive  factors in an HCV infected population with advanced
brosis treated in real life conditions with full dose pegin-
erferon  alfa 2a or alfa 2b plus bodyweight-adjusted dose of
ibavirin  and to evaluate the adverse events related to treat-
ent.
atients  and  methods
 multicentric, retrospective study was  conducted in six
niversity  Hospitals in Brazil. The Ethics Committee of the
niversity  Hospital of Botucatu School of Medicine, São Paulo,
pproved  the study protocol. All patients’ data were codi-
ed  to guarantee anonymity. At each participating center the
ocal  principal investigator identiﬁed eligible patients based
n  predeﬁned criteria and data was  entered on a database.
he  inclusion criteria were  as follows: naïve HCV-RNA pos-
tive  patients with bridging ﬁbrosis (METAVIR score F3) or
irrhosis  (METAVIR score F4) at liver biopsy. Patients who
ad  clinical or ultrasonographic evidence of cirrhosis were
onsidered  as cirrhotics without liver biopsy and were  also
llocated  as F4. Cirrhotic patients were considered as decom-
ensated  at baseline if they were  presented with jaundice,
scites, esophageal varices or hepatic encephalopathy. The
xclusion  criteria were: HIV or HBV co-infection, hepatocel-
ular  carcinoma at baseline and Child–Pugh score higher than
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Patients  were treated with full dose PEG-IFN alpha-2a or
alpha-2b  and ribavirin according to body weight. Patients with
<75  kg received 1000 mg/d of ribavirin and those whose weight
was  ≥75 kg were treated with 1250 mg/d. Treatment was  based
on  the criteria established by the Brazilian Ministry of Health
for  treatment of chronic HCV infection. Treatment would be
interrupted at week 12 if less than a 2-log drop from baseline
viral  load was identiﬁed. In those with at least 2-log drop in
viral  load at week 12, a new viral load was  performed at week
24  and if the HCV-RNA was detectable, treatment was  stopped
as  well. All patients were treated for 48 weeks regardless of
genotype.
Data  included in the analysis were as follows: gender, age,
weight  at baseline, ﬁbrosis level deﬁned by METAVIR score,
viral  genotype, HCV-RNA levels at baseline and at weeks 4,
12,  24, 48 and 72, ribavirin dose (mg/kg), and platelet count.
Laboratory baseline data included in the analysis were liver
enzymes  (ALT, AST and GGT) and liver function tests (albu-
min,  bilirubin and INR). Child–Pugh score was registered for F4
patients.  Reasons of reduction of either peginterferon or RBV
and  for early treatment discontinuation were  also recorded.
Three  modalities of treatment response were  deﬁned: non-
responders  (detectable HCV-RNA w24 or w48  or absence of
a  two log reduction in the viral load at week 12), relapsers
(HCV-RNA undetectable at the end of treatment but detectable
24  weeks after the end of treatment), and sustained virologi-
cal  response (undetectable HCV-RNA at week 24 after the end
of  treatment). An intent-to-treat analysis was  carried out in
patients  receiving at least one dose of medication and those
patients  who did not complete the treatment regimen were
classiﬁed  as non-responders.
Statistical  analysis
Data was  recorded and analyzed using SPSS 17.0, Chicago, IL,
USA.  Nominal variables are presented in absolute and relative
frequencies. For continuous variables, descriptive statistics
are  presented as mean and standard deviation, with minimum
and  maximum values. The associations between selected fac-
tors and SVR were analyzed by using the chi-square and
Fisher’s  exact tests when indicated. A stepwise logistic regres-
sion  analysis was  performed in order to identify the variables
independently related to SVR. Variables who presented a p-
value <0.20 at the univariate analysis were  included in the
regression  analysis. A signiﬁcance level of 5% was  adopted.
Results
Three hundred and eight patients were included (62% male,
mean  age of 52 ± 10 yrs, median body weight was  76 ± 15 kg).
Regarding  genotype, 232 (75%) patients were  genotype 1 and 72
(23%)  genotype 3. Two additional patients were  genotype 2 (1%)
and genotype was inconclusive in 2 others (1%). Patients with
genotype  2 and inconclusive genotype were excluded from the
analysis.  Stage 3 ﬁbrosis was  present in 121 (39%) and stage
4  (cirrhosis) in 187 (61%) patients. In patients with stage 4,
the  median Child Pugh score was 5.5–9 Mean baseline HCV-
RNA  was 5.55 ± 0.94 log. Mean platelet count at baseline was
141.735  ± 59.649/mL.
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Table 1 – Comparative analysis between F3 and F4 patients according to baseline and on-treatment variables (n = 304).
Variable F3 (n = 121) F4 (n = 187) p-Value
Age (yrs ± SD) 49 ± 11 52 ± 9 0.16
Gender (% male) 35  65 0.034
PEG-IFN alfa 2b (%) 39 60 0.85
Genotype 1 (%) 41 59 0.134
Abnormal GGT(%) 37 63 0.022
Platelet count (×103) 161 (35–203) 120 (37–135) <0.001
Ribavirin (mg/kg) 14.6 ± 2.07 14.5 ± 2.10 0.9
RVR (%) 45 55 0.135
EVR (%) 46 54 0.16
PEG-IFN dose reduction (%) 15 85 <0.001
Ribavirin dos reduction (%) 41 59 0.53
RR (%) 9 13 <0.001
NR (%) 45 62 <0.001
SVR (%) 59 
Death (n) 0 
Table 2 – Logistic regression analysis (n = 304) – ﬁnal
model.
Variable OR 95% CI
F3 × F4 2.5 1.2–5.4
Genotype 3 vs. 1 5.3 2.3–12.0
RVR 4.3 2.0–9.1
Efﬁcacy  of  treatment
The global SVR rate was  34%, 11% were relapsers and 55%
were  nonresponders. SVR rates did not differ signiﬁcantly
between patients treated with peginterferon alfa 2a or alfa 2b
(34% × 32%, respectively; p = 0.24). Genotype 1 patients had a
higher  SVR if the ribavirin dose was  not reduced (p = 0.02). On
the  other hand, in genotype 3 patients, SVR was  higher for
those  whose peginterferon dose was  not reduced from base-
line  (0.002).
In  the comparison between genotype 1 and genotype 3
patients,  the SVR was  36% and 77% respectively (p < 0.001). The
comparative  analysis between F3 and F4 patients is shown in
Table  1. The SVR rates according to Child–Pugh score were
26%  for Child A and 18% for Child B. On the multivariate
analysis that included all patients (Table 2), the variables inde-
pendently  associated with SVR were genotype 3 (OR 7.6, CI
3.12/20),  ﬁbrosis stage 3 (OR 3.43, CI 1.49/7.93) and undetectable
HCV-RNA at 4th week of treatment (OR 8.69, CI 3.53/21.27). In
the logistic regression analysis that included only F4 patients,
the  independent factors related to SVR were  genotype 3, RVR
and  fewer Child Pugh score points. This is shown in Table 3.
Table 3 – Logistic regression analysis including only F4
patients  and SVR: ﬁnal model (n = 187).
Variable OR 95% CI
Genotype 3 vs. 1 3.49 1.072–11.404
RVR Child 0.1232.028 0.031–0.486
1.164 – 3.532
OR – odds ratio; CI – conﬁdence interval; RVR – rapid virological
response;  Child – score Child Pugh.31 <0.001
6 <0.001
The positive (PPV) and negative predictive values (NPV) of
SVR  were  calculated for each genotype according to the pres-
ence  of RVR and EVR. The results are displayed in Table 4.
Adverse  events  and  adherence  to  treatment
Treatment interruption occurred in 94 (31%) patients. Treat-
ment  was  suspended in 39 (13%) patients due to failure to
obtain  a 2-log drop at week 12 (non-responder patients). Treat-
ment  was  stopped due to cirrhosis decompensation in 12
patients  (4%) and to non-adherence in 15 patients (5%). Over-
all,  death occurred in six (1.9%) patients, all with liver cirrhosis.
Among  them, two were Child Pugh A and four patients Child
Pugh  B. The causes of death were sepsis in three patients,
meningitis in one patient, liver decompensation in one patient
with  overt encephalopathy and upper gastrointestinal bleed-
ing  in another patient.
Discussion
This study aimed at evaluating the SVR rate in patients with
advanced  ﬁbrosis and its tolerance to treatment. It included
a  substantial number of patients with cirrhosis. The main
ﬁnding  was a SVR rate of 34%, which is considered high for
advanced  ﬁbrosis patients taking into account that 61% were
cirrhotic.  In the subgroup of cirrhotic patients, SVR rate was
25%  including all genotypes and 18% when only genotype 1
is  considered. It is a real life study that shows that treatment
should be encouraged in this group owing to the potential ben-
eﬁts  related to SVR in HCV patients with advanced ﬁbrosis.
Two  meta-analyses by Zhang et al. and Cammà  et al. suggested
Table 4 – Positive and negative predictive factors for SVR
according  to genotype and viral kinetics in patients with
advanced  ﬁbrosis (n = 304).
Genotype With RVR With EVR
1 PPV  (%) 47 62
NPV (%) 82 93
3 PPV (%) 82 68
NPV (%) 54 86
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hat IFN therapy could efﬁciently reduce HCC development
n  patients with HCV-related cirrhosis.12,13 Thus all efforts
hould be made to treat this population. On the other hand we
howed that a careful approach is necessary regarding adverse
vents  mainly in cirrhotic patients.
Nowadays in many  countries the standard of care treat-
ent  for genotype 1 patients is the triple therapy with
rotease inhibitors.14,15 However, in some countries in South
merica  and Europe this treatment is not yet available due
o  many  concerns, mainly economic issues. Patients with
dvanced  ﬁbrosis might not wait too long to start treatment
wing  to the risk of decompensation of liver disease, which is
round 2–6% a year.16 The protease inhibitors are very potent
nd  confer higher SVR when compared to treatment with PEG-
FN  and ribavirin.17–20 However, many  adverse events have
een  described and an ongoing study in cirrhotic patients
ith  protease inhibitors has demonstrated serious adverse
vents  including death. It is possible that some naïve cirrhotic
atients  that were  not able to ﬁnish therapy with protease
nhibitors due to adverse events could beneﬁt from treatment
ith  PEG-IFN and ribavirin, albeit with smaller chance of SVR.
his  should be encouraged mainly in those cirrhotic patients
ith  RVR. In the present study, RVR was  an independent
ariable related to SVR. This was  previously demonstrated
nd although cirrhotic patients rarely achieve RVR this has
 strong positive predictive value for SVR.21,22 Another point
hat  should be considered for naïve patients with advanced
brosis  whose treatment interruption was  related to adverse
vents  is the IL28B genotype. Although it was  not evaluated in
his study, we  could wonder whether CC genotype patients
ight  have attained SVR if treatment was  not interrupted
arly. Although it has been demonstrated in this study that
ETAVIR  F4 patients have a lower SVR rate when treated with
EG-IFN  and RBV, maybe this regimen might be tried in CC
aïve  cirrhotic patients with side effects related to protease
nhibitors. These patients could not wait for a better treatment
ue  to their advanced disease.
In this real life study adherence to treatment was  good, only
%  were non-adherent and 4% of the cirrhotic patients had
reatment  interrupted owing to cirrhosis decompensation. It
hould be pointed out that six patients died. This is lower
han  the 16% previously reported by Giannini et al. However,
heir  study included only cirrhotic patients.23 In the ongoing
tudy  on cirrhotics and protease inhibitors the mortality was
igh  owing to adverse events, mainly sepsis. It is well known
hat  cirrhosis is a risk factor for infection owing to decreased
psonization capacity among other related factors.24 This way,
lthough  treatment with PEG-RBV or triple therapy should be
ncouraged, these patients must have a very close follow-up
n  order to avoid severe complications that might be more  fre-
uent and more  intense in this population when comparing
o  non-cirrhotic patients.
In  genotype 2 and 3 Hepatitis C patients, PEG-IFN and riba-
irin  are still the mainstay of therapy. In the present study,
enotype  3 patients comprised 24% of the total sample and
enotype  2 were not included in the analysis owing to the
mall  number of genotype 2 patients. The SVR rate among
enotype 3 F3 patients was  77% and 46% in the cirrhotic group.
n  genotype 3 patients, viral kinetics showed a remarkable role.
chievement of RVR had a high positive predictive value for 1 4;1  8(1):48–52  51
SVR (82%) in genotype 3, much  higher than the positive pre-
dictive  value of RVR for genotype 1 which was  47%. Thus, if
available,  an HCV-RNA should also be performed at week 4 of
treatment  in genotype 3 patients.
There is no question that F3 patients with advanced ﬁbro-
sis  should always be put on therapy even before pangenotype
therapy is available for this group. In this study, genotype 1
patients  treated with PEG-RBV had a 38% SVR while genotype
3  patients achieved 77% SVR. Even if these patients do not
achieve  SVR the beneﬁt of having been treated with PEG-RBV
and  thus getting to know their viral kinetics proﬁle will prob-
ably  help to estimate their chance for SVR in a future triple
therapy  based regimen.18,19
RBV dose was closely related to SVR in genotype 1 and PEG-
IFN  in genotype 3. Ribavirin dose has already been reported to
be related to higher SVR rates.24 In the present study, the mean
dose  of RBV was 14.5 mg/kg overall, and no difference was
observed  between the different genotypes. RBV dose reduction
was  more  frequent in cirrhotic patients with either genotype.
In  the present study, the rate of treatment interruption
was similar to other studies. None of the decompensated cir-
rhotic  patients obtained SVR. In addition, this subgroup had
more  adverse events as well as treatment interruption when
compared  to Child Pugh A cirrhotic patients included in this
study.  Previous studies showed that treatment discontinua-
tion  is higher among decompensated cirrhotic patients but
these  studies also discuss the importance of trying to eradicate
HCV  in this difﬁcult to treat population.23 Treating this popu-
lation  with protease inhibitors may  be even more  difﬁcult. So
far, protease inhibitors are not indicated to decompensated
cirrhotic patients. Death rate was higher in the present study
and  all deaths occurred in cirrhotic patients mainly in those
with  a Child Pugh score B. Septicemia was  the most frequent
etiology among those patients who died and this has already
been  shown in another real life study with triple therapy.24
Thus, all efforts must be done in order to diagnose and treat
cirrhotic  patients while still at Child Pugh A stage. The deci-
sion  to treat a cirrhotic Child B patient should be made on an
individual  basis, optimizing interferon dose when necessary
in  case of adverse events. Furthermore, these patients can be
treated once they are at a liver transplant center.
In conclusion, patients with advanced ﬁbrosis are very
difﬁcult to treat mainly if they already have liver cirrhosis.
Although treatment may  be the only chance to eradicate HCV
infection  in these patients and thus prevent further disease
progression and decompensation it may  also cause severe
adverse  events and death. A very careful evaluation of cirrhotic
patients  must be performed before treatment is indicated
and  careful monitoring of viral kinetics and adverse events
is  required during treatment.
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